



Contra Costa Health Plan
P&T Formulary Update
March 12, 2019

Volume 9

Changes effective: 3/27/2019

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On March 12, 2019 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
<ul style="list-style-type: none"> • ACEI & ACEI Combination • ARB & ARB Combination • Statin & Statin Combination • Phosphodiesterase 5 Inhibitor • Beta Blockers • Calcium Channel Blockers • Cholinesterase Inhibitor • Cystic Fibrosis Agents • Ophthalmic Antihistamines 	<ul style="list-style-type: none"> • PCSK9 Inhibitors • Pulmonary Arterial Hypertension • Leukotriene Receptor Antagonist • Anticholinergic • ESAs • ICS/LABA Combination • Short acting Beta Agonists • Muscle Relaxants • Second Generation Antihistamines
Drug Monographs	
<ul style="list-style-type: none"> • None 	
Prior Authorization Criteria Updates	
<p><u>New criteria was created for the following agents: None</u></p> <p><u>Updates were made to the criteria for the following agents:</u></p> <ul style="list-style-type: none"> • Nicardipine, Nicardipine CR • Epinastine (Elestat) • Emedastine(Emadine), Nedocromil (Alocril), Olopatadine (Pazeo) • Zileuton (Zyflo) • Scopolamine patch (Trasderm-Scop) • Dronedarone (Multaq) • Clonidine ER (Kapvay) • Omalizumab (Xolair) • Evolocumab (Repatha) • Entecavir (Baraclude) <p><u>Updates were made to the criteria for the following classes:</u></p> <ul style="list-style-type: none"> • ACEI & ACEI Combination • ARB & ARB Combination 	

- Statin & Statin Combination
- Beta Blockers
- Calcium Channel Blockers
- Cystic Fibrosis Agents
- Ophthalmic Antihistamines
- PCSK9 Inhibitors
- Leukotriene Receptor Antagonist
- Anticholinergic
- ESAs
- ICS/LABA Combination
- Short acting Beta Agonists
- Muscle Relaxants
- Second Generation Antihistamines

Criteria reviewed and unchanged:

- PDE 5 Inhibitors
- Cholinesterase Inhibitor
- IV Iron
- Pulmonary Arterial Hypertension Agents
- Alprostadil (Caverject, Muse)
- Roflumilast (Daliresp)
- Clobazam (Onfi)
- Dabigatran (Pradaxa)
- Pregabalin (Lyrica)

The following drugs were added to the CCHP formulary:

- Zyban (Bupropion SR)
- Adalat CC (nifedipine ER)
- Protopic (tacrolimus) ointment

Guest Speaker(s)

- None

CCHP P&T Committee approved the following modifications to the formulary:

Medication Name & Dosage Strength	Approved Formulary Changes
Bupropion SR 150mg tabs (Zyban)	Added to the formulary with tier 1 status.
Nifedipine ER (Adalat CC) 30, 60, 90mg tablets	Added to the formulary with tier 1 status
Tacrolimus 0.03% ointment, 0.1% ointment (Protopic)	Added to the formulary with tier 2 status (QL 30g)
Entecavir	Tablet splitting is no longer a requirement for the 0.5mg dose

New Product Reviews

